全文获取类型
收费全文 | 19126篇 |
免费 | 1413篇 |
国内免费 | 1234篇 |
出版年
2024年 | 27篇 |
2023年 | 233篇 |
2022年 | 379篇 |
2021年 | 938篇 |
2020年 | 576篇 |
2019年 | 819篇 |
2018年 | 809篇 |
2017年 | 570篇 |
2016年 | 846篇 |
2015年 | 1129篇 |
2014年 | 1371篇 |
2013年 | 1472篇 |
2012年 | 1711篇 |
2011年 | 1545篇 |
2010年 | 976篇 |
2009年 | 949篇 |
2008年 | 1061篇 |
2007年 | 987篇 |
2006年 | 808篇 |
2005年 | 695篇 |
2004年 | 541篇 |
2003年 | 530篇 |
2002年 | 445篇 |
2001年 | 347篇 |
2000年 | 303篇 |
1999年 | 300篇 |
1998年 | 180篇 |
1997年 | 164篇 |
1996年 | 160篇 |
1995年 | 123篇 |
1994年 | 87篇 |
1993年 | 74篇 |
1992年 | 113篇 |
1991年 | 83篇 |
1990年 | 73篇 |
1989年 | 53篇 |
1988年 | 46篇 |
1987年 | 45篇 |
1986年 | 38篇 |
1985年 | 51篇 |
1984年 | 8篇 |
1983年 | 17篇 |
1982年 | 9篇 |
1981年 | 11篇 |
1980年 | 7篇 |
1979年 | 7篇 |
1978年 | 6篇 |
1977年 | 5篇 |
1974年 | 5篇 |
1969年 | 11篇 |
排序方式: 共有10000条查询结果,搜索用时 265 毫秒
861.
862.
863.
Hongyan Liu Xiaoming Qiang Qing Song Wei Li Yuxi He Chanyuan Ye Zhenghuai Tan Yong Deng 《Bioorganic & medicinal chemistry》2019,27(6):991-1001
A series of 4′-OH flurbiprofen Mannich base derivatives were designed, synthesized and evaluated as potential multifunctional agents for the treatment of Alzheimer’s disease. The biological screening results indicated that most of these derivatives exhibited good multifunctional activities. Among them, compound 8n demonstrated the best inhibitory effects on self-induced Aβ1-42 aggregation (65.03% at 25.0?μM). Moreover, this representative compound also exhibited good antioxidant activity, biometal chelating ability and anti-neuroinflammatory activity in vitro. Furthermore, compound 8n displayed appropriate blood-brain barrier permeability. These multifunctional properties highlight compound 8n as promising candidate for further development of multi-functional drugs against AD. 相似文献
864.
Synthesis and biological evaluation of BMS-986120 and its deuterated derivatives as PAR4 antagonists
Panpan Chen Shenhong Ren Hangyu Song Cai Chen Fangjun Chen Qinglong Xu Yi Kong Hongbin Sun 《Bioorganic & medicinal chemistry》2019,27(1):116-124
BMS-986120 is a PAR4 antagonist that is being investigated as an antiplatelet agent in phase I clinical trial. An improved synthesis of BMS-986120 has been developed. Based on the novel synthetic approach to BMS-986120, a series of deuterated derivatives of BMS-986120 have been synthesized and biologically evaluated to search for more potent antiplatelet agents. The in vitro antiplatelet assay by turbidimetry demonstrated that PC-2 and PC-6 had IC50 values of 6.30?nM and 6.97?nM, respectively, versus BMS-986120 with an IC50 of 7.80?nM. The result of in vitro metabolic stability study showed that all of the deuterated compounds had similar half-life (T1/2) and intrinsic clearance (Clint) in comparison with BMS-986120. Further probing the metabolic profile of BMS-986120 is worth being conducted. 相似文献
865.
866.
867.
868.
869.
Chemokines and their receptors participate in the development of cancers by enhancing tumor cell proliferation, angiogenesis, invasion, metastasis and penetration of tumor immune cells. It remains unclear whether CXC chemokine ligand 4 (CXCL4)/CXC chemokine receptor 3-B (CXCR3-B) can be used as an independent molecular marker for establishing prognosis for breast cancer patients. We evaluated CXCL4 and CXCR3-B expression in 114 breast cancer tissues and 30 matched noncancerous tissues using immunohistochemistry and western blot, and determined the correlation between their expression and clinicopathologic findings. We observed that breast cancer tissues express CXCL4 strongly and CXCR3-B weakly compared to noncancerous tissues. Strong CXCL4 expression was detected in 94.7% and weak CXCR3-B expression was detected in 78.9% of the tissues. Therefore, CXCL4/CXCR3-B might play a crucial role in breast cancer progression. We found no significant correlation between CXCL4 and age, tumor stage, tumor grade or TNM stage. CXCR3-B was associated significantly with tumor grade. Moreover, the Chi-square test of association showed that the expression of CXCL4/CXCR3-B might be an independent prognostic marker for breast cancer. Therefore, we suggest that CXCR3-B is an indicator of poor prognosis and may also be a chemotherapeutic target. 相似文献
870.